FDA Approves Amivantamab-Vmjw With Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer With EGFR Exon 19 Deletions or L858R Variants

September 20, 2024

On September 19, 2024, the U.S. Food and Drug Administration (FDA) approved (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19) amivantamab-vmjw (Rybrevant®) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution variants whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.

fda update

Efficacy was evaluated in MARIPOSA-2 (NCT04988295), a randomized, open-label, multicenter trial involving 657 patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution variants and disease progression on or after receiving osimertinib. Patients were randomized 1:2:2 to receive amivantamab-vmjw with carboplatin and pemetrexed (amivantamab + CP), carboplatin and pemetrexed (CP), or amivantamab-vmjw as part of another combination regimen.

The major efficacy outcome measure was progression-free survival (PFS), as assessed by blinded independent central review (BICR), between amivantamab + CP and CP. Overall response rate (ORR) per BICR and overall survival (OS) were key secondary outcome measures. Median PFS was 6.3 months (95% CI = 5.6, 8.4) in the amivantamab + CP arm and 4.2 months (95% CI = 4.0, 4.4) in the CP arm (HR = 0.48 [95% CI = 0.36, 0.64], p < 0.0001). The confirmed ORR was 53% (95% CI = 44, 62) in the amivantamab + CP arm and 29% (95% CI = 23, 35) in the CP arm (p < 0.0001).

At the prespecified second interim analysis of OS, with 85% of the deaths needed for the final analysis, the groups had no statistically significant difference in OS. The stratified OS hazard ratio was 0.73 (95% CI = 0.54, 0.99).

The most common adverse reactions reported in at least 20% of patients were rash, infusion-related reactions, fatigue, nail toxicity, nausea, constipation, edema, stomatitis, decreased appetite, musculoskeletal pain, vomiting, and COVID-19 infection.

The recommended amivantamab-vmjw dose is based on baseline body weight. See the full prescribing information on Drugs@FDA (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm) for specific dosage information.

The applicant used the Assessment Aid (https://www.fda.gov/about-fda/oncology-center-excellence/assessment-aid) to facilitate the FDA’s review, which was conducted under Project Orbis (https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis), an initiative of the FDA Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, the FDA collaborated with the Australian Therapeutic Goods Administration, Brazilian Health Regulatory Agency, and Health Canada. The application reviews are ongoing at the other regulatory agencies.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm) or by calling 800-FDA-1088.

For assistance with single-patient applications for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate (https://www.fda.gov/about-fda/oncology-center-excellence/project-facilitate) at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov (mailto:OncProjectFacilitate@fda.hhs.gov).


Copyright © 2024 by the Oncology Nursing Society. User has permission to print one copy for personal or unit-based educational use. Contact pubpermissions@ons.org for quantity reprints or permission to adapt, excerpt, post online, or reuse ONS Voice content for any other purpose.